BridGene Biosciences, Inc.

BridGene Biosciences is a biotechnology company focusing on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases.

Currently, about 90% of proteins associated with diseases cannot be targeted by traditional therapies due to the lack of a known addressable binding site. BridGene intends to change this by using its proprietary Chemoproteomics platform, IMTAC™ (Isobaric Mass Tagged Affinity Characterization). IMTAC™ enables the screening of small molecules against all the proteins in live cells to discover drug candidates for high value and hard-to-drug targets that cause diseases.

Bringing new drugs to previously undruggable targets means new therapies with new mechanisms for unmet medical needs. The ultimate goal is to expand small molecule drug discovery approaches and scope at an unprecedented speed and success rate.